Schedule at a Glance

Media | Gallery | Contact

Home / 2019 SABCS^® / Program / Schedule at a Glance

To view the 2019 SABCS Abstracts, please click here.
2019 SABCS Financial Disclosures
Monday, 12/9/19
12:00 pm - 5:00 pm	REGISTRATION - Main Lobby
Tuesday, 12/10/19
8:00 am - 7:00 pm	REGISTRATION - Main Lobby

11:45 am - 1:45 pm	WORKSHOPS
	Molecular Biology in Breast Oncology - Hemisfair Ballroom - 3rd Level Moderator: Carlos L. Arteaga, MD UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, TX Antibody-drug conjugates in cancer: Principles for synthesis and preclinical development Gail Lewis Phillips Genentech, Inc. South San Francisco, CA Defining a cancer dependency map William C. Hahn, MD, PhD Dana-Farber Cancer Institute Boston, MA Approaches to targeting the anti-apoptotic machinery in breast cancer Geoffrey Lindeman, MB BS, FRACP, PhD The Walter & Eliza Hall Institute of Medical Research Parkville, AUSTRALIA Novel target discovery by longitudinal deep spatial & molecular analysis of breast cancers Joe Gray, PhD Oregon Health & Science University Portland, OR

	Developing Novel Therapeutics in the Metastatic Setting - Stars at Night Ballroom 1&2 - 3rd Level Moderator: Virginia G. Kaklamani, MD UT Health San Antonio San Antonio, TX Window versus neoadjuvant trial - choose wisely Alastair M. Thompson, BSc (Hons), MB ChB, MD, FRCSEd Baylor College of Medicine Houston, TX Therapeutic development in the era of precision medicine: Paradigm shift from maximum tolerated dose (MTD) to optimal biological dose (OBD) Aditya Bardia, MD, MPH Massachusetts General Hospital Harvard Medical School Boston, MA Design and analysis of window and neoadjuvant trials Meredith Regan, ScD Dana-Farber Cancer Institute Harvard Medical School Boston, MA How to talk to patients about participating in clinical trials Patricia Spears, BSc UNC Lineberger Comprehensive Cancer Center Chapel Hill, NC

1:45 pm - 2:00 pm	BREAK

2:00 pm - 7:00 pm	EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1&2, 3, 4 and Hemisfair Ballroom - 3rd Level Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

2:00 pm - 3:30 pm	Immunotherapy for Triple-Negative Breast Cancer – Stars at Night Ballroom 3 - 3rd Level Moderator: Sylvia Adams, MD NYU Langone Health New York, NY The emerging role of immunotherapy for the treatment of early and advanced breast cancer Rita Nanda, MD University of Chicago Chicago, IL Detecting and managing immunotherapy-related toxicities wisely Peter Schmid, MD, PhD Barts Cancer Institute London, UNITED KINGDOM Assessment of PD-L1 in breast cancer to predict response to immunotherapy David L. Rimm, MD, PhD Yale University School of Medicine New Haven, CT Evolving Opportunities to Personalize Radiation Decisions - Stars at Night Ballroom 4 - 3rd Level Moderator: Reshma Jagsi, MD, DPhil University of Michigan Ann Arbor, MI Guiding decisions to omit radiotherapy after breast-conserving surgery for DCIS. Can genomic biomarkers help? Eileen Rakovitch, MD, MSc, FRCPC Sunnybrook Health Sciences Centre Toronto, CANADA Evolving opportunities to personalize radiation decisions - Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer Corey Speers, MD, PhD University of Michigan Ann Arbor, MI Guiding selection of RT approach after lumpectomy Simona Shaitelman, MD University of Texas MD Anderson Cancer Center Houston, TX Breast Cancer Prevention – Stars at Night Ballroom 1&2 - 3rd Level Moderator: Judy E. Garber, MD, MPH Dana-Farber Cancer Institute Boston, MA Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them Maxine S. Jochelson, MD Memorial Sloan Kettering Cancer Center New York, NY Management of high risk women: considering the time-frame Seema A. Khan, MD Northwestern University Chicago, IL Low dose tamoxifen and other approaches to improve chemoprevention uptake Andrea De Censi, MD E.O. Ospedali Galliera Genova, ITALY Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations ‐ Hemisfair Ballroom - 3rd Level Moderator: Carlos L. Arteaga, MD UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, TX Adaptive resistance to hormonal therapy Suzanne A.W. Fuqua, PhD Baylor College of Medicine Houston, TX Single cell transcriptomcs reveals multi-step adaptation to endocrine therapy Luca Magnani, PhD Imperial College London London, UNITED KINGDOM The genomic landscape of endocrine-resistant metastatic breast cancer Pedram Razavi, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY

3:45 pm - 5:15 pm	Multidisciplinary Approaches to Optimizing Surgical Therapy for Hormone Receptor Positive Breast Cancer – Stars at Night Ballroom 3 - 3rd Level Moderator: Armando Giuliano, MD Cedars-Sinai Medical Center Los Angeles, CA Neoadjuvant therapy for hormone receptor positive breast cancer: Advances and challenges Otto Metzger, MD Dana-Farber Cancer Institute Boston, MA Regional management of the axilla prior to systemic therapy Melissa L. Pilewskie, MD Memorial Sloan Kettering Cancer Center New York, NY Surgical considerations AFTER preoperative therapy for hormone receptor positive breast cancer Tari Ann King, MD Dana-Farber Cancer Institute Brigham and Women's Cancer Center Boston, MA Implementation of Genetic Testing in Breast Cancer Patients – Stars at Night Ballroom 4 - 3rd Level Moderator: Virginia G. Kaklamani, MD UT Health San Antonio San Antonio, TX Who should have germline testing for hereditary breast cancer? Nadine Tung, MD Beth Israel Deaconess Medical Center Boston, MA Alternative practical models for genetic services in the era of increased demand Banu Arun, MD University of Texas MD Anderson Cancer Center Houston, TX Breast cancer genetic testing: moving from cancer risk assessment to therapeutic biomarker Judith Balmaña, MD, PhD Vall d'Hebron University Hospital Barcelona, SPAIN Conversations on Tough Topics Surrounding Cancer Care – Stars at Night Ballroom 1&2 - 3rd Level Moderator: Susan Rafte Community Advocate, Baylor College of Medicine Breast Center Houston, TX Progression of disease and end of life: How to break bad news Eric P. Winer, MD Dana-Farber Cancer Institute Boston, MA The toll on healthcare providers Sharon H. Giordano, MD, MPH, FASCO University of Texas MD Anderson Cancer Center Houston, TX The financial costs and burden of breast cancer care Rachel A. Greenup, MD, MPH Duke Cancer Institute Durham, NC Panel Discussion Thelma P. Brown University of Alabama at Birmingham Birmingham, AL Katherine O'Brien Metastatic Breast Cancer Network New York, NY Endocrine Therapy in 2020 - Hemisfair Ballroom - 3rd Level Moderator: Mothaffar Rimawi, MD Baylor College of Medicine Houston, TX Adjuvant endocrine therapy in 2020: It's complicated Ruth O'Regan, MD University of Wisconsin Madison Madison, WI Future directions in endocrine therapy for advanced HR+/HER2- breast cancer Erica L. Mayer, MD, MPH Dana-Farber Cancer Institute Harvard Medical School Boston, MA Everything comes at a price - Toxicity, cost and adherence to endocrine therapy Dawn Hershman, MD Columbia University Medical Center New York Presbyterian Hospital New York, NY

5:30 pm - 7:00 pm	Discussing Risk in the Context of GEP Testing - Stars at Night Ballroom 3 - 3rd Level Moderator: Lesley Fallowfield, BSc, DPhil Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School Brighton, UNITED KINGDOM Discussing risk & uncertainty with patients in the context of GEP testing Lesley Fallowfield, BSc, DPhil Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School Brighton, UNITED KINGDOM Communicating risk information, talking by numbers Valerie Ann Jenkins, DPhil, BSc Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School Brighton, UNITED KINGDOM Breast Cell Fate Control and Plasticity – Stars at Night Ballroom 4 - 3rd Level Moderator: Yi Li, PhD Baylor College of Medicine Houston, TX Cellular plasticity, fate, potential and lineage commitment of mammary gland stem cells Cedric Blanpain, MD, PhD Universite Libre de Bruxelles Bruxelles, BELGIUM Understanding breast cancer using a developmental perspective Geoffrey Wahl, PhD Salk Institute for Biological Studies La Jolla, CA Cell fate plasticity during breast cancer development - where is the translational utility? Christina Scheel, MD Helmholtz Center Munich Institute of Stem Cell Research Neuherberg, GERMANY Tailoring Adjuvant Therapies Based on Neoadjuvant Response - Stars at Night Ballroom 1&2 - 3rd Level Moderator: Charles E. Geyer, MD Virginia Commonwealth University Massey Cancer Center Richmond, VA The biology and plasticity of residual disease after neoadjuvant treatment Charles M. Perou, PhD University of North Carolina Chapel Hill, NC Neoadjuvant systemic treatment (NST): Tailoring response by subtype Jenny C. Chang, MD Houston Methodist Hospital Houston, TX Local treatment in patients who achieve pathologic complete response Julia White, MD The Ohio State University Columbus, OH Targeted Treatment Beyond PARP1 Inhibition - Hemisfair Ballroom - 3rd Level Moderator: Alexander Bishop, DPhil Greehey Children's Cancer Research Institute UT Health San Antonio San Antonio, TX Clinical indications of PARP1 inhibitors and other targets Melinda L. Telli, MD Stanford University Medical Center Stanford, CA Targeted DNA repair in cancer and new NUDT5 inhibitors to block hormone signalling to target breast cancer Thomas Helleday, PhD University of Sheffield Sheffield, UNITED KINGDOM Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments Violeta Serra, PhD Vall d'Hebron Institute of Oncology Barcelona, SPAIN

7:30 pm - 10:00 pm	OPEN SATELLITE EVENT presented by PVI, Peer View Institute for Medical Education - Marriott Rivercenter
	On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum For further information and to register for this event, visit : PeerView.com/TNBC19
Wednesday, 12/11/19
7:00 am - 5:15 pm	REGISTRATION - Main Lobby

7:00 am - 8:00 am	CONTINENTAL BREAKFAST - Hall 2

8:00 am - 8:15 am	WELCOME AND OPENING REMARKS - Hall 3 Carlos L. Arteaga, MD UT Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas, TX Virginia G. Kaklamani, MD UT Health San Antonio San Antonio, TX C. Kent Osborne, MD Baylor College of Medicine Houston, TX

8:15 am - 8:45 am	PLENARY LECTURE 1 - Hall 3
	Stromal Cells and Matrix Remodeling as Essential Regulators of the Tumor Microenvironment Ellen Puré, PhD University of Pennsylvania Philadelphia, PA
8:45 am - 11:15 am	GENERAL SESSION 1 - Hall 3

10:45 am - 5:00 pm	EXHIBITS - Exhibit Hall 2

11:15 am - 12:00 pm	WILLIAM L. MCGUIRE MEMORIAL LECTURE – Hall 3
	What would Bill think? Joseph Sparano, MD Montefiore Medical Center Bronx, NY

12:00 pm - 1:00 pm	BREAK

12:00 pm - 1:00 pm	CAREER DEVELOPMENT FORUM, sponsored by Eisai, Inc. - Room 304

1:00 pm - 2:00 pm	CLINICAL SCIENCE FORUM - Stars at Night Ballroom 3&4 - 3rd Level
	Frontiers in HER2 Positive Breast Cancer Moderator: Sibylle Loibl, MD German Breast Group Frankfurt, GERMANY Origins and clinical implications of HER2 heterogeneity Andrea L. Richardson, MD, PhD Johns Hopkins Medicine Baltimore, MD Emerging therapies for HER2 positive breast cancer Shanu Modi, MD Memorial Sloan Kettering Cancer Center New York, NY Systemic therapy for breast cancer brain metastases Nancy U. Lin, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA
1:00 pm - 2:00 pm	BASIC SCIENCE FORUM 1 - Stars at Night Ballroom 1&2 - 3rd Level
	RNA Rewiring in Breast Cancer Progression Moderator: Chonghui Cheng, MD, PhD Baylor College of Medicine Houston, TX RNA methylation in human cancer Chuan He, PhD University of Chicago Chicago, IL Genome regulation by long noncoding RNA Howard Chang, MD, PhD Stanford University Stanford, CA

2:15 pm - 3:15 pm	SUSAN G. KOMEN^® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES - Hall 3
	SUSAN G. KOMEN^® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE
	Deciphering Stem and Progenitor Cells to Understand Breast Cancer Jane Visvader, PhD and Geoffrey Lindeman, MBBS, FRACP, PhD The Walter and Eliza Hall Institute (WEHI) Melbourne, AUSTRALIA
	SUSAN G. KOMEN^® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH
	The Molecular Etiology of Luminal-Type Breast Cancer Matthew J. Ellis, MB BChir, BSc, PhD, FRCP Baylor College of Medicine Houston, TX

3:15 pm - 5:00 pm	GENERAL SESSION 2 - Hall 3

5:00 pm - 7:00 pm	Spotlight Session 1: Immunotherapy in Breast Cancer: New Directions - Hemisfair Ballroom 1 - 3rd Level

5:00 pm - 7:00 pm	Spotlight Session 2: CDK4/6 Inhibitors Resistance and Biomarkers - Stars at Night Ballroom 1&2 - 3rd Level

5:00 pm - 7:00 pm	Spotlight Session 3: Risk/Prevention - Stars at Night Ballroom 3&4 - 3rd Level

5:00 pm - 7:00 pm	POSTER SESSION 1 & Reception - Hall 1

7:30 pm - 9:30 pm	OPEN SATELLITE EVENT hosted by Research to Practice - Marriott Rivercenter
	Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer For further information and to register for this event, visit: http://www.researchtopractice.com/Meetings/SA2019

7:30 pm - 10:00 pm	OPEN SATELLITE EVENT hosted by Clinical Care Options - Marriott Riverenter
	Leveraging Evolving Data Sets to Inform Treatment Decision-Making in HR-Positive, HER2-Negative Advanced Breast Cancer
Thursday, 12/12/19
6:45 am - 5:15 pm	REGISTRATION - Main Lobby

7:00 am - 9:00 am	Spotlight Session 4: Targeting HER2 and DNA Repair - Stars at Night Ballroom 1&2 - 3rd Level

7:00 am - 9:00 am	Spotlight Session 5: Immunooncology Biomarkers and the Immune Landscape of Breast Cancer - Stars at Night Ballroom 3&4 - 3rd Level

7:00 am - 9:00 am	POSTER SESSION 2 & continental breakfast - Hall 1

9:00 am - 9:30 am	PLENARY LECTURE 2 - Hall 3
	The Role of Radiotherapy Combined With Immunotherapy in Oligometastatic Cancer Ralph R. Weichselbaum, MD University of Chicago Chicago, IL

9:30 am - 11:30 am	GENERAL SESSION 3 - Hall 3

10:45 am - 5:00 pm	Exhibits - Hall 2

11:30 am - 12:00 pm	AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH - Hall 3
	Essential Genes and Cistromes in Breast Cancer Myles Brown, MD Dana-Farber Cancer Institute Boston, MA

12:00 pm - 1:00 pm	BREAK

12:00 pm - 1:00 pm	CAREER DEVELOPMENT FORUM - Room 304

1:00 pm - 2:00 pm	CASE DISCUSSION 1 - Stars at Night Ballroom 1&2 - 3rd Level Moderator: Mothaffar Rimawi, MD Baylor College of Medicine Houston, TX

1:00 pm - 2:00 pm	TRANSLATIONAL SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level
	Proteogenomics of Breast Cancer, from Discovery to Precision Medicine Moderator: Matthew J. Ellis, MD, BChir, BSc, PhD, FRCP Baylor College of Medicine Lester & Sue Smith Breast Center Houston, TX Advanced enabling technologies for cancer proteomics Tao Liu, PhD Pacific Northwest National Laboratory Richland, WA Proteogenomic landscape of prospectively collected breast cancer Michael Gillette, MD, PhD Broad Institute Cambridge, MA Proteogenomics and clinical translation Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP Baylor College of Medicine Houston, TX

2:15 PM - 3:15 pm	MINI-SYMPOSIUM 1 - Hall 3
	Future of Immuno-oncology in Breast Cancer Moderators: Jenny C. Chang, MD Houston Methodist Hospital Houston, TX and Helen Heslop, MBChB, MD, DSc Baylor College of Medicine Houston, TX Immunotherapy in breast cancer: enhancing response to checkpoint blockade Elizabeth A. Mittendorf, MD, PhD Dana-Farber Cancer Institute Brigham and Women's Cancer Center Boston, MA T cell-based immunotherapy for a "public" neoantigen derived from a PIK3CA hotspot mutation Christopher A. Klebanoff, MD Memorial Sloan Kettering Cancer Center New York, NY

3:15 pm - 5:00 pm	GENERAL SESSION 4 - Hall 3

5:00 pm - 7:00 pm	Spotlight Session 6: Local Regional Therapy/DCIS - Hemisfair Ballroom 1 - 3rd Level

5:00 pm - 7:00 pm	Spotlight Session 7: The Science of ER Resistance and Emerging Clinical Strategies - Stars at Night Ballroom 1&2 - 3rd Level

5:00 pm - 7:00 pm	Spotlight Session 8: The Metastatic Landscape - Drug Resistance and Metastasis Biology - Stars at Night Ballroom 3&4 - 3rd Level

5:00 pm - 7:00 pm	POSTER SESSION 3 & Reception - Hall 1

7:30 pm	OPEN SATELLITE EVENT presented by Harborside Medical Education - Marriott Rivercenter
	Breast Cancer Brain Metastases: Key Strategies for Optimal Management For further information and to register for this event, visit https://www.eventbrite.com/e/breast-cancer-brain-metastases-key-strategies-for-optimal-management-registration-71692294583

7:30 pm	OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter
	Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer For further information and to register for this event, visit http://www.researchtopractice.com/Meetings/SA2019
Friday, 12/13/19
6:45 am - 5:15 pm	REGISTRATION - Main Lobby

7:00 am - 9:00 am	Spotlight Session 9: Detection and Treatment Response Assessment - Stars at Night Ballroom 1&2 - 3rd Level

7:00 am - 9:00 am	Spotlight Session 10: Toxicity, Tolerability & Cost - Stars at Night Ballroom 3&4 - 3rd Level

7:00 am - 9:00 am	POSTER SESSION 4 & continental breakfast - Hall 1

9:00 am - 9:45 am	DEBATE - Hall 3
	Mastectomy should not be offered to patients who are breast conservation candidates when modern radiotherapy is available Chairman: Richard Crownover, MD, PhD UT Health San Antonio San Antonio, TX Lawrence B. Marks, MD, FASTRO University of North Carolina at Chapel Hill School of Medicine Chapel Hill, NC Alastair M. Thompson, ALCM, BSc(Hons) MBChB, MD, FRCSEd(Gen) Baylor College of Medicine Houston, TX

9:45 am - 11:30 am	GENERAL SESSION 5 - Hall 3

10:45 am - 5:00 pm	EXHIBITS - Hall 2

11:30 am- 12:00 pm	2019 AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, SUPPORTED BY THE BREAST CANCER RESEARCH FOUNDATION - Hall 3
	Novel Non-canonical Functions of EZH2 in Triple Negative Breast Cancer Celina Kleer, MD University of Michigan Medical School Ann Arbor, MI

12:00 pm - 1:00 pm	BREAK

12:00 pm - 1:00 pm	NETWORKING WITH THE EXPERTS - Hall 2

1:00 pm- 2:00 pm	CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level Moderator: Mothaffar Rimawi, MD Baylor College of Medicine Houston, TX

1:00 pm - 2:00 pm	TRANSLATIONAL SCIENCE FORUM 2 – Stars at Night Ballroom 3&4 - 3rd Level
	The Communal Road to Metastasis: CTC Clusters Moderator: Rachel Schiff, PhD Baylor College of Medicine Lester & Sue Smith Breast Center Houston, TX CTC clusters, cancer stemness, and new treatment strategies Huiping Liu, MD, PhD Northwestern University Chicago, IL Biology, vulnerabilities and clinical implications of CTC clusters Nicola Aceto, PhD University of Basel Basel, SWITZERLAND

2:15 pm - 3:15 pm	MINI-SYMPOSIUM 2 - Hall 3
	Targeting the Cell Cycle Kinase CDK 4/6 and Beyond Moderator: Angela DeMichele, MD, MSCE Abramson Cancer Center University of Pennsylvania Philadelphia, PA Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches Sarat Chandarlapaty, MD, PhD Memorial Sloan Kettering Cancer Center New York, NY Targeting the cell cycle - Beyond CDK4/6 inhibition Rinath Jeselsohn, MD Dana-Farber Cancer Institute Boston, MA

3:15 pm - 5:00 pm	GENERAL SESSION 6 - Hall 3

5:00 pm - 7:00 pm	POSTER SESSION 5 & Reception - Hall 1

6:00 pm - 7:30 pm	SPECIAL SESSION - Stars at Night Ballroom 3&4 - 3rd Level
	View from the Trenches: What Will You Do On Monday Morning? Moderator: Ruth O'Regan, MD University of Wisconsin Carbone Cancer Center Madison, WI Panel Members: Nadia Harbeck, MD, PhD Ludwig Maximilian University of Munich Munich, GERMANY E. Shelley Hwang, MD, MPH Duke University Durham, NC Debra A. Patt, MD, MPH Texas Oncology Austin, TX Bárbara Segarra-Vázquez, DHSc University of Puerto Rico San Juan, PR Joseph Sparano, MD Montefiore Medical Center Albert Einstein College of Medicine Bronx, NY

7:30 pm	OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter Data + Perspectives: Clinical Investigators Explore the Current and Future Management of HER2- Positive Breast Cancer For further information and to register for this event, visit http://www.researchtopractice.com/Meetings/SA2019

Saturday, 12/14/19

6:45 am - 9:00 am	Registration - Main Lobby

7:00 am - 9:00 am	POSTER SESSION 6 & continental breakfast - Hall 1

9:00 am - 11:00 am	The Year in Review - Hall 3
	Moderator: C. Kent Osborne, MD Baylor College of Medicine Houston, TX Basic science Alana L. Welm, PhD University of Utah Huntsman Cancer Institute Salt Lake City, UT Translational research Geoffrey Lindeman, MBBS, FRACP, PhD The Walter & Eliza Hall Institute of Medical Research Parkville, AUSTRALIA Early breast cancer Masakazu Toi, MD, PhD Kyoto University Kyoto, JAPAN Metastatic breast cancer Sara Hurvitz, MD University of California, Los Angeles Los Angeles, CA

11:00 am	Adjournment


12:00 pm - 1:45 pm

Home Symposium Overview 2019 SABCS^® Best Of SABCS^® Past Meetings Media Contact

In collaboration with Astro

and

7979 WURZBACH ROAD, MC 8824, SAN ANTONIO, TX 78229 USA

V. 210-450-1550

F. 210-450-1560

SABCS@UTHSCSA.EDU

Home / 2019 SABCS® / Program / Schedule at a Glance

Home / 2019 SABCS^® / Program / Schedule at a Glance